Cardinal Health 414, LLC has been awarded a firm fixed price purchase order contract valued at $27,037.50 by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide up to 15 millicuries of fluorodeoxyglucose (FDG), a radioactive chemical used for imaging and scans, with delivery by January 17, 2025. No set-aside designation was applied. This award supports the NIH's medical research efforts through the delivery of radiopharmaceuticals by Cardinal Health 414, a subsidiary of Cardinal Health Inc. that holds several indefinite delivery contracts with value in the millions of dollars to regularly supply pharmaceutical products including specialized radioactive isotopes to various Department of Veterans Affairs networks and facilities, the Department of Defense, and NIH centers.
Generated 2/16/24, 9:57 AM